WUXI BIO Issues 0.25 Million New Shares via Option Exercises, Expanding Total Share Capital to 4.14 Billion in March 2026

Bulletin Express04-09

WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital.

The authorised share capital remained unchanged at 6.00 billion ordinary shares (USD 50,000 nominal), each with a par value of USD 1/120,000.

Issued share capital rose by 252,200 shares—equivalent to 0.25 million—bringing the total outstanding shares to 4.14 billion as of 31 March 2026. All new shares originated from exercises under the Pre-IPO Share Option Scheme across five grant tranches.

Option exercises generated proceeds of USD 0.07 million during the month. Post-exercise, 31.94 million options under the Pre-IPO scheme remain outstanding.

In addition to existing options, the company has authority to issue up to 98.50 million shares under two share award programmes: • Restricted Share Award Scheme: 89.26 million shares • Global Partner Program Share Award Scheme: 9.23 million shares

No treasury shares were held or transferred, and no warrants or convertible securities were outstanding.

Management confirmed that the public float comfortably met the Hong Kong Stock Exchange’s minimum 15% requirement at month-end.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147398971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147398971","market":"hk","top_or_hot":-1,"title":"WUXI BIO Issues 0.25 Million New Shares via Option Exercises, Expanding Total Share Capital to 4.14 Billion in March 2026","media":"Bulletin Express","content":"<p>WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital.</p>\n<p>The authorised share capital remained unchanged at 6.00 billion ordinary shares (USD 50,000 nominal), each with a par value of USD 1/120,000.</p>\n<p>Issued share capital rose by 252,200 shares—equivalent to 0.25 million—bringing the total outstanding shares to 4.14 billion as of 31 March 2026. All new shares originated from exercises under the Pre-IPO Share Option Scheme across five grant tranches.</p>\n<p>Option exercises generated proceeds of USD 0.07 million during the month. Post-exercise, 31.94 million options under the Pre-IPO scheme remain outstanding.</p>\n<p>In addition to existing options, the company has authority to issue up to 98.50 million shares under two share award programmes:\n• Restricted Share Award Scheme: 89.26 million shares  \n• Global Partner Program Share Award Scheme: 9.23 million shares</p>\n<p>No treasury shares were held or transferred, and no warrants or convertible securities were outstanding.</p>\n<p>Management confirmed that the public float comfortably met the Hong Kong Stock Exchange’s minimum 15% requirement at month-end.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WUXI BIO Issues 0.25 Million New Shares via Option Exercises, Expanding Total Share Capital to 4.14 Billion in March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWUXI BIO Issues 0.25 Million New Shares via Option Exercises, Expanding Total Share Capital to 4.14 Billion in March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital.</p>\n<p>The authorised share capital remained unchanged at 6.00 billion ordinary shares (USD 50,000 nominal), each with a par value of USD 1/120,000.</p>\n<p>Issued share capital rose by 252,200 shares—equivalent to 0.25 million—bringing the total outstanding shares to 4.14 billion as of 31 March 2026. All new shares originated from exercises under the Pre-IPO Share Option Scheme across five grant tranches.</p>\n<p>Option exercises generated proceeds of USD 0.07 million during the month. Post-exercise, 31.94 million options under the Pre-IPO scheme remain outstanding.</p>\n<p>In addition to existing options, the company has authority to issue up to 98.50 million shares under two share award programmes:\n• Restricted Share Award Scheme: 89.26 million shares  \n• Global Partner Program Share Award Scheme: 9.23 million shares</p>\n<p>No treasury shares were held or transferred, and no warrants or convertible securities were outstanding.</p>\n<p>Management confirmed that the public float comfortably met the Hong Kong Stock Exchange’s minimum 15% requirement at month-end.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1147398971","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147398971","pubTimestamp":1775724108,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital. The authorised share capital remained unchanged at 6.00 billion...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"药明生物通过期权行权发行25万股新股，2026年3月总股本扩大至41.4亿股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital.\nThe authorised share capital remained unchanged at 6.00 billion ordinary shares (USD 50,000 nominal), each with a par value of USD 1/120,000.\nIssued share capital rose by 252,200 shares—equivalent to 0.25 million—bringing the total outstanding shares to 4.14 billion as of 31 March 2026. All new shares originated from exercises under the Pre-IPO Share Option Scheme across five grant tranches.\nOption exercises generated proceeds of USD 0.07 million during the month. Post-exercise, 31.94 million options under the Pre-IPO scheme remain outstanding.\nIn addition to existing options, the company has authority to issue up to 98.50 million shares under two share award programmes:\n• Restricted Share Award Scheme: 89.26 million shares  \n• Global Partner Program Share Award Scheme: 9.23 million shares\nNo treasury shares were held or transferred, and no warrants or convertible securities were outstanding.\nManagement confirmed that the public float comfortably met the Hong Kong Stock Exchange’s minimum 15% requirement at month-end.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147398971","isCrawlerRequest":true}